

## Active Protocol Studies - Summa Health System

KEY
<i>ACH: Akron City Hospital</i>
<i>SBH: Summa Barberton Hospital</i>
<i>RMH: Robinson Memorial Hospital</i>
<i>SWRH: Summa Western Reserve</i>

Contacts	Phone	Pager	Title
<i>Joyce Neading</i>	<i>330-375-4221</i>	<i>3265</i>	<i>Program Director</i>
<i>Lynn Kaplan</i>	<i>330-375-6121</i>	<i>1642</i>	<i>Clinical Research Coordinator</i>
<i>Ann Stone</i>	<i>330-375-6578</i>	<i>1886</i>	<i>Clinical Research Nurse</i>
<i>Sarah Stanaszek</i>	<i>330-375-6390</i>	<i>3339</i>	<i>Clinical Research Nurse</i>
<i>Nicole Buie</i>	<i>330-615-4132</i>	<i>1185</i>	<i>Clinical Research Nurse</i>

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Sus-pended	Title	Eligibility Requirements
<b>All Cancers</b>									
<i>All Cancers</i>	Merck V212	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy	Solid tumor or hematologic malignancy;no hematopoietic cell transplant (HCT); ≥ age 18 & IS receiving cytotoxic or immunosuppressive chemo OR ≥age 50 not in remission & may or may not be receiving chemo. Life expect. 12 mos; prior hx of Chickenpox
<b>BRAIN</b>									
<i>Anaplastic glioma</i>	RTOG 0834	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial	No prior chemo and no prior radiotherapy to the brain; PS 0-2; prior surgery for a low grade tumor is allowed, provided histological; Start of radiotherapy within 8 days from randomization; start of radiotherapy within 7 weeks (49 days) from surgery
<i>Brain Mets from Breast Cancer</i>	RTOG 1119	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG	Invasive breast cancer; HER2+; ≥ 1 measurable, new or progressive after SRS or surgical resection (1-3 mets);Karnofsky ≥60;No Prior WBRT;No Prior lapatinib tx;No Leptomeningeal dz
<i>Glioblastoma - Recurrent</i>	RTOG 1205	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation vs. Bevacizumab Alone as a Treatment for Recurrent Glioblastoma	Glioblastoma or variants;≥6 mos completion prior tx;karnofsky ≥70;< 2 relapses;no multifocal,infratentorial or leptomeningeal evd of recurrent dz;no prior tx w/inhibitor of VEGF or VEGFR;recurrent or persistent tumor <5cm;or meetcriteria per protocol
<i>Glioblastoma or Gliosarcoma - Recurrent</i>	RTOG 1122	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma	Glioblastoma, gliosarcoma, glioblastoma w/ oligodendroglial features, giant cell glioblastoma; Karnofsky≥70; Chemo >28 days; RT>90 days;No surgical procedure < 28 days; No prior tx with anti-VEGF; < 2 relapses; no hx blood clots
<i>Glioblstoma</i>	RTOG 0913	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase I/II Trial of Concurrent RAD001 (Everolimus) with Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma	GBM (WHO Grade IV);Gliosarcoma OK; No recurrent/malignant glioma;No mets; Karnofsky 70-100; No prior temozolomide, mTOR inhibitor, Gliadel wafers or other intratumoral or intracavitary tx; No prior RT,radiosensitizers or chemo to the head, neck or brain

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<b><i>Glioblastoma (recurrent)</i></b>	RTOG 0929 Bev-failure: perm closed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma (Now recruiting for Phase II)	Intracranial glioblastoma or gliosarcoma for the phase II component;evidence of tumor progression ≤ past 14 days; Completed a course of RT; Pts in phase II must also have completed ≥ 2 courses of temozolomide; Karnofsky ≥70; no hx of seizures
<b><i>Low Grade Gliomas</i></b>	ECOG E3F05	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas	Grade 2 astrocytoma, oligodendroglioma or oligoastrocytoma; ≥1 of the following: uncontrolled headaches, seizures, focal neurological symptoms or Cognitive symptoms or deficits OR new or progressive enhancement; > 2wks brain surgery; no prior tx; PS ≥60
<b><i>Resected Brain Mets</i></b>	N107C (RTOG credit) ACH Only	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial of Post-Surgical Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease	≤ 4 brain mets; at least 1 lesion resected; non-CNS primary site; unresected lesions ≤ 3.0 cm, PS 0-2; no prior cranial RT; no planned chemo; no germ cell, small cell or lymphoma
<b><i>WBRT &amp; Stereotactic for 1-3 mets</i></b>	N0574 (RTOG credit) ACH only	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With 1-3 Brain Metastases	1-3 brain mets, maximum tumor dimension <= 3 cm. per lesion, PS 0-2; no prior RT; no chemo during trt; ineligible primaries: germ cell, small cell, lymphoma
<b><i>BREAST</i></b>									
<b><i>DCIS</i></b>	B-43	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy	HER2+,No pN1,must submit tumor block for central review prior to randomization. DO NOT ORDER HER-2 STUDIES (Done centrally)
<b><i>Early Stage</i></b>	RTOG 1005 (Cosmesis component w/no chemo closed)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer	Stage I or II + 1 more requirement (see protocol) OR Stage 0 with grade 3 DCIS OR Stage 0, I, II resected by lumpectomy after neoadj systemic tx; No mets; No prior breast ca; No T4, N2 or N3, or M1; no prior RT; PS 0-2
<b><i>HER2 Neg Node + or High Risk Node -</i></b>	B-49	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer	HER2-,unilateral invasive adenoca,pT1-3;pN0, pN1(pN1mi, pN1a, pN1b, pN1c),pN2a, pN3a, or pN3b; If pN0,must be:ER- & PgR- OR >2.0 cm OR T1c and ER+ and either grade 3 OR Oncotype DX ≥25;rand ≤ 84 days;no T4 or inflammatory;no mets;PS 0-1;central rev tissue
<b><i>HER2 neg; ER/PR +</i></b>	G028509 (Peggy)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II, Randomized Study of Paclitaxel with GDC-0941 versus Paclitaxel with Placebo in Patients with Locally Recurrent or Metastatic Breast Cancer	HER2-; ER/PR+ loc recur or met; PS 0-1; no prior chemo; cap chemo >2wks; prior RT for bone met >2wks; no insulin dep diabetes;no CNS mets

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<b>HER2 neg; Node +; ER+ and/or PR+;</b>	S1007 (NSABP credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Tri	1-3 node+; ER+ and/or PR+; HER2 neg; Recurrence Score (RS) by Oncotype DX® ≤ 25; Prior DCIS OK only if treated with mastectomy alone; No metastatic dz; PS 0-2; No prior chemo or endocrine tx
<b>HER2-Positive</b>	SCUSF 0806 (not endorsed yet)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®)	HER2-positive breast ca; males ok; Scheduled to receive adjuvant or neoadjuvant trastuzumab therapy; Hormone receptor and menopausal status not specified; No prior trastuzumab or anthracyclines; No known cardiac history; no met dz; no ARB's
<b>Local Recurrence</b>	RTOG 1014	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma	Locally recurrent breast cancer < 120 days; Tumor ≤ 3 cm; Initial lumpectomy followed by whole breast RT > 1 year; whole-body PET-CT scan OR CT scan of the chest, abdomen, pelvis, & bone scan < 120 days; PS 0-1; No concurrent tx including trastuzumab
<b>Metastatic</b>	ECOG 2108	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Trial of the Value of Early Local Therapy (Surgery + RT after Chemo vs continued chemo only as needed for control of distant disease) for the Intact Primary Tumor in Patients with Metastatic Breast Cancer	Stage IV intact primary(not recurrent);prior DCIS OK if no recurrence;both M & F;no synch/contraltrl ca;≥1 distant met;CNS mets OK if LE >6 mos;had 16 wks chemo;no dz prog w/in 2 wks enrolling;candidates for complete resection w/ free margins following RT
<b>Node + or High Risk Node - HER2-Low</b>	B-47	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Trial Comparing Chemotherapy Alone to Chemotherapy + Trastuzumab in Women with Node+ or High-Risk Node- HER2-Low Invasive Breast Cancer	AdenoCa; primary pT1-3, ipsilateral nodes pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b; No T4 tumors or inflammatory dz; no mets; no synchronous or previous contralateral invasive dz; HER2-low; PS 0-1; no prior tx;
<b>GI</b>									
<b>Colon</b>	CALGB 80702 (NSABP Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer	Stage III completely resected; ≥ 1+ lymph node; no rectal ca; PS 0-2;No hx of upper GI ulceration, bleeding, or perforation ≤ 3 years; No concurrent NSAIDs > 2x wk or aspirin at > 325 mg ≥ 3 times per week;
<b>Colon Prevention</b>	P-5	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Statin (Crestor) Polyp Prevention Trial in Patients with Resected Colon Cancer	Stage 0, I, II or III adenocarcinoma of the colon w/ curative intent <1 year;complete resection;pre-op or post-op colonoscopy <180 days; >30 days since prior statins & prior investigational agents; no chronic use of NSAIDS (low dose aspirin OK);PS 0-1
<b>Colorectal</b>	ECOG 7208 Temporarily suspended	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy	AdenoCa of the colon or rectum;adv dz,K-ras wild type;meas dz;had prior first-line therapy w/oxaliplatin-based fluoropyrimidine-containing chemo + bevacizumab; progression <42 days; no brain or CNS mets;PS 0-1;bevacizumab 28-90 days;surgery >28 days

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>Colorectal</i>	OCCPI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome	Newly diagnosed with colorectal adenocarcinoma starting 1/1/13; sufficient tumor available to perform MSI testing
<i>Esophageal</i>	RTOG 1010	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma	Stage T1, N1-2 or T2-3, N0-2; No T1,N0 or T4 disease; No metastatic dz; able to have curative resection within 56 days after completion of chemoRT; No evidence of tracheoesophageal fistula or invasion into trachea or major bronchi; PS 0-2; No prior tx
<i>Esophagus</i>	S1201 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Pts Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	Unresectable adv or met adenoca of esophagus, stomach or GEJ; no prior tx for met dz;HER-2 neg; prior neo or adj tx ≥ 180 days;PS 0-1;no motor or sensory neuropathy;no plans for other concurrent tx; central review (Arm 1:FOLFOX; Arm 2:Taxotere+Irinotecan)
<i>GEJ</i>	S1201 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Pts Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	Unresectable adv or met adenoca of esophagus, stomach or GEJ; no prior tx for met dz;HER-2 neg; prior neo or adj tx ≥ 180 days;PS 0-1;no motor or sensory neuropathy;no plans for other concurrent tx; central review (Arm 1:FOLFOX; Arm 2:Taxotere+Irinotecan)
<i>Liver (Locally advanced or metastatic)</i>	CALGB 80802 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)	Locally adv or met HCC;meas dz; no CNS/brain mets;PS 0-2; No prior allografts; no prior VEGF; prior tx OK if >6 mo; no prior chemo for met dz; > 4 wks prior locoregional tx, interferon, surgery, or RT;
<i>Pancreas</i>	RTOG 0848	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (Gemzar +/- Erlotinib; Step 2: +/- RT)	Resected pancreatic cancer, stage T1-3, N0-1, M0; No prior chemo; No prior total pancreatectomy, distal pancreatectomy, or central pancreatectomy; No prior RT to the region that would result in overlap of RT fields; No recurrent pancreatic cancer; PS 0-1
<i>Pancreas</i>	S1115 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy	Distant, mets;No end/neuroend tumors, or ampullary; syst tx ≥14days; sx ≥14days; RT≥7days; meas or non meas dx; PS 0-1; must have 1 prior gemcitabine ≥28 days; no uncontrolled diabetes
<i>Rectal, locally advanced</i>	N1048 (RTOG credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II/III trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation vs Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	Rectal adenoca; T2N1, T3N0, T3N1; candidate for sphincter-sparing surgical resection; tumor 5-12 cm from anal verge; PS 0-2;Radiologically measurable or clinically evaluable dz per Section 11; no APR at baseline; no bowel obstruction, no prior pelvic RT
<i>Stomach</i>	S1201 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Pts Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	Unresectable adv or met adenoca of esophagus, stomach or GEJ; no prior tx for met dz;HER-2 neg; prior neo or adj tx ≥ 180 days;PS 0-1;no motor or sensory neuropathy;no plans for other concurrent tx; central review (Arm 1:FOLFOX; Arm 2:Taxotere+Irinotecan)

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<b>GU</b>									
<i>Bladder</i>	RTOG 0926	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Re-Staging	T1G2 or T1G3 transitional cell ca that has recurred < 18 months after initial treatment for ≤ T1 tumors; T1, NX or NO, M0 without hydronephrosis; No pN+ or > T1 disease; no mets; PS 0-1; no prior chemo or RT
<i>Renal</i>	S0931 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	EVEREST: EVERolimus for Renal Cancer Ensuimg Surgical Therapy, A Phase III Study (Everolimus vs Placebo X 54 weeks)	Renal cell ca; full resection (radical or partial nephrectomy); neg margins; bilateral renal tumors OK; no residual or metastatic dz; no prior tx; Zubrod PS 0-1
<i>Renal Advanced Sarcomatoid</i>	ECOG 1808	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features	Renal cell carcinoma with sarcomatoid features; meas dz not resectable; treated brain mets OK if off steroids .≥2 weeks; No prior systemic therapy for metastatic dz; > 2 wks RT; PS 0-2
<i>Renal Metastatic</i>	ECOG 4805 Re-opened to Arm A only	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma	Unresectable or met. renal cell ca;clear cell;meas.dz;failed a TKI;prior immunotx cytokine w/ interleukin2 & interferon alpha only;no prior chemo, cellular, vaccine or hormonal tx;prior RT OK if meas dz outside RT port ;PS 0-2; no CNS mets; RT ≥ 3 wks
<b>GYN</b>									
<i>Carcinosarcoma (uterus or ovary)</i>	GOG 0261	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Trial of Paclitaxel + Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary	Uterine, fall tube, peritoneal or ovarian carcinosarcoma w/≥ 1 of these:newly diagnosed dz,Stage I-IV,recurrent or chemo-naive;PS 0-2;No prior chemo;RT > 4 wks;hormonal tx > 1 wk;No planned RT after or during study tx;may be unstaged;meas or non-meas dz
<i>Cervical</i>	GOG 0127-W Temp. Closed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Phase II Evaluation of ABT-888 (IND # 77840, NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699), and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix	Persistent or recurrent squamous cell ca, adenosquamous ca, adenocarcinoma or non-squamous cell; meas. dz; Patients must not be eligible for a higher priority GOG protocol, if one exists; RT ≥ 4 wks; 1 prior tx ≥ 3wks; PS 0-2; no surgery or RT on study
<i>Cervical</i>	GOG 0221 Blood and Tissue Submission Only	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Glycoprotein and Glycan Profiling In Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA > 4 cm, IIB To IVA) Undergoing Pelvic and Para-Aortic (Abdominal) Lymphadenectomy	Newly diagnosed cervical ca (Stages IB2, IIA > 4 cm, IIB to IVA) undergoing pelvic and para-aortic lymphadenectomy; must have a block or 25 unstained sections of primary tumor available; Register prior to surgery w/in 4 weeks
<i>Cervical</i>	GOG 0263	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy	Squamous cell,adenosquamous,adenocarcinoma; Stage I-IIA;radical hysterectomy & pelvic lymphadenectomy;no tumor in the parametria, pelvic lymph nodes, or other extra-uterine site; PS 0-2; surgery 3-8 weeks;no prior RT or chemo; Brachy boost not allowed

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>Cervical</i>	GOG 0274 RTOG 1174	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial	FIGO 2008 Stage IB1 node+, IB2, II, IIIB or IVA; no prior chemo or pelvic RT; no Stage IIIA; no mets; no prior or planned hysterectomy; no interstitial brachy tx permitted; no IMRT and Rapid Arc permitted; PS 0-2
<i>Cervical</i>	GOG 0278	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) For Stage IA1 (LVSI+) and IA2-IB1 (</=2cm) Cervical Cancer	Squamous cell, adenoca or adenosquamous cell of cervix; Stage IA1 (LVSI+), IA2, IB1 (≤2cm) any grade; Must have had a cone biopsy or LEEP w/ neg margins; invasion <10mm; no mets; neg pelvic nodes; PS 0-2;
<i>Cervical</i>	GOG 9926 Temp. Closed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Phase I Evaluation of Extended Field Radiation Therapy with Concurrent Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes	Squamous, adenocarcinoma, or adenosquamous cervical cancer: FIGO IB, IIA, IIB, IIIA, IIIB, IVA, with positive para-aortic lymph nodes; No prior tx of any kind; PS 0-2.
<i>Cervical</i>	RTOG 0724	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy	Stage IA2, IB, or IIA disease; Must have had radical hysterectomy; No neuroendocrine histology; PS 0-1; No prior chemo for the current cervical cancer; No prior RT to pelvis that would result in overlap of RT fields
<i>Cervical &amp; Endometrial</i>	RTOG 1203 (Time-C)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Study of Standard vs. IMRT Pelvis Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (Time-C)	Dx ≤ 90days; Hysterectomy ≤ 49days prior to reg; no dist mets; zubro 0-2; no prior RT to pelvis; no prior plat chem. Tx; no para-aortic nodal dz; margins >3mm
<i>Cervical, Uterine, Vulvar</i>	GOG 0244	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors and Impact in Newly Diagnosed Patients	Pts undergoing hyst/BSO & pelvic lymphadenectomy (Stage I-II uterine) OR radical hyst or trachelectomy & pelvic (Stage IA-IIA cervical) OR Stage I-IV vulvar cancer having vulvectomy or radical local excision w/ lymphadenectomy; PS 0-2
<i>Endometrial</i>	GOG 0258	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Stage III or IVA endometrial ca per FIGO 2009; PS 0-2; no recurrent endometrial ca; no carcinosarcoma; no prior pelvic or abdominal RT; no prior chemo for endometrial ca; no residual > 2cm (FIGO 2009 Stage I or II clear cell or serous with + pelvic washings
<i>Endometrial - Recurrent</i>	GOG 0229-K Temp. Closed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Phase II Evaluation of BIBF 1120 (IND# 113086) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Recurrent or persistent endometrial ca, refractory to tx; meas dz; must have 1 target lesion; not eligible for higher priority protocol; must have had 1 prior chemo tx; no prior non-cytotoxic tx; no brain mets
<i>Gestational Trophoblastic Neoplasia (GTN) - Low Risk</i>	GOG 0275	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Trial of Pulse Actinomycin-D versus Multi-day Methotrexate for the Management of Low Risk Gestational Trophoblastic Neoplasia	FIGO Stage I, II, or III for low-risk gestational trophoblastic neoplasia (GTN): post molar GTN or choriocarcinoma; second curettage OK; WHO risk score 0-6; No non-gestational choriocarcinoma or prior chemo; No prior pelvic RT; No PSTT or ETT; PS 0-2

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>Leiomyosarcoma</i>	GOG 0131-H Temp. Closed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus	Persistent or recurrent dz refractory to tx; meas. dz.; Not eligible for a higher priority GOG protocol; Must have had 1 prior regimen that included a taxane; no brain mets; PS 0-2; >1wk hormonal tx; >3 wks prior tx; >4 wks RT
<i>Leiomyosarcoma</i>	GOG 0277	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) versus Observation for Uterus-limited, High Grade Uterine Leiomyosarcoma	High risk uterine LMS, FIGO stage I; had complete hysterectomy; no mets; PS 0-1; no prior chemo with docetaxel, gemcitabine or doxorubicin ever; no prior whole pelvic RT; no recurrent LMS; no HIV
<i>Ovarian</i>	GOG 0268	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Evaluation of Temsirolimus (CCI-779) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary	Newly diagnosed stage III or IV clear cell ovarian ca; PS 0-2; Neuro function ≤ grade 1; No severely impaired lung function; No prior tx with a mTOR inhibitor, paclitaxel, or carbo; No prior RT or chemo to any portion of the abdomen or pelvis; surgery 2-12 wks
<i>Ovarian or Fallopian Tube</i>	GOG 0241	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial of Open Label Carboplatin and Paclitaxel +/- Bevacizumab Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian Cancer or Fallopian Tube Cancer (MEOC)	Mucinous ca of ovary or fall. Tube; FIGO stage II-IV new or recurrent chemo-naive OR recurrent stage I; No primary peritoneal ca; No brain mets; PS 0-2; Life expect >3 mo; No prior chemo, RT or mouse antibody; surgery >4 weeks & none planned during tx; no warfarin
<i>Ovarian, Fallopian Tube and Primary Peritoneal Cancer</i>	DUKE 1810	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Epidemiology of Ovarian Cancer in African American Women	African-American women with newly diagnosed invasive epithelial ovarian, fallopian tube or peritoneum cancer
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0186-K	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) (IND #116059) versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Recurrent or pers dz; PS 0-2; 1 prior platinum-based tx req; OK to have had 2 adtl cytotoxic regimens with no more than 1 non-platinum, non-taxane regimen. No active CNS dz; Trt with weekly paclitaxel for recurrent or persistent dz is NOT allowed
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0212	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Trial of Paclitaxel or Polyglutamate Paclitaxel (CT-2103) or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer	Primary peritoneal or Stage III or IV epithelial ovarian or fallopian tube ca with either optimal ≤ 1 cm residual dz or suboptimal residual dz after initial surgery; had 5-8 cycles tx ≤ 12 wks; no sx of persistent ca, normal CT scan & CA-125; PS 0-2
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0235 Blood and Tissue Submission	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	GOG 0235 A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy	FIGO stage III or IV invasive ovarian, primary peritoneal, or fall. tube receiving primary chemo for newly dx dz; no recurrent dz, carcinosarcoma or borderline epithelial tumors; no prior chemo for any abdominal tumors; no neoadj; full surgical staging req.
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0260 Suspended effective 4.5.12	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Meas dz; must have had 1 prior platinum-based chemo tx; must be platinum-resistant or refractory; not elig. for higher GOG protocol; PS 0-2; >1 wk prior hormonal tx; >3 wks prior biological or immunotherapy; see RT tx rule

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0267 QOL STUDY	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian tube, and Peritoneal Cancer	Recurrent or persistent ovarian, peritoneal or fallopian tube platinum-resistant cancer(< 6 months from date of last platinum tx to recurrence); life expectancy > 6 months; any PS but must be able to verbally consent and participate in the first assessment
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 3001 TRINOVA-3	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase 3 Randomized,Double-Blind,Placebo-Controlled,Multi-Center Study of AMG 386 With Paclitaxel & Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers (Amgen #2010129)	FIGO III-IV ov, prim peri or fall.tube receiving 1st line tx w/ Taxol/carbo x 6 cycles.IIIA or IIIB must have had PDS ≤12 wks prior to reg.IIIC or IV PDS ≤12 wks prior OR Plan to have IDS following 3 cycles Taxol/carbo + AMG 386. PS 0-1;No prior tx or CNS
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 3003	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized,Double-Blind,Placebo-Controlled Phase II Study Of VTX-2337 In Combination With Pegylated Liposomal Doxorubicin (PLD) In Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (VentiRx)	Recurrent or persistent dz; must have had 1 prior platinum-based tx; must be platinum resistant; platinum-refractory are NOT eligible; Meas dz; 1; PS 0-1; no prior anthracyclines; no CNS;may have 1 prv tx for recurrent or persis dz; no invest drug <30days
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0273 ≥ age 70	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	GOG 0273 Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer	≥ age 70;Adenoca of ovary, peritoneum or fallopian tube;FIGO I, II, III & IV;no prior tx except for surgery;register ≤ 8 weeks confirmation of dx or 12 wks of primary/staging surgery;PS 0-3;phys choice primary surgery vs chemo + 2 chemo regimen choices
<i>Ovarian, Fallopian tube, or Peritoneal Cavity Cancer</i>	GOG 0213	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase III Randomized Controlled Clinical Trial of Carboplatin & Paclitaxel Alone or In Combination with Bevacizumab Followed By Bevacizumab & Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Peritoneal & Fallopian Tube Cancer	Recurrent, meas. disease; dz-free=6 mo; MUST BE CANDIDATES FOR CYTOREDUCTIVE SURGERY AND CONSENT TO HAVE THEIR SURGICAL TREATMENT DETERMINED BY RANDOMIZATION; PS 0-2; only 1 prior chemo tx; no prior RT; no CNS;No concurrent immunotherapy or radiotherapy
<i>Uterine carcinosarcoma</i>	GOG 0130-F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Recurrent or progressive uterine carcinosarcoma; meas dz; > 3 wks prior tx; >1 wk prior hormonal tx; PS 0-2; not eligible for higher priority GOG protocol; prior tx with Taxane required
<i>Uterine Recurrence</i>	GOG 0238	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Biopsy proven recurrent endometrial ca confined to the pelvis and/or vagina;No evidence of extra pelvic dz;PS 0-2;Prior primary surgical debulking OK; no exenterative surgery;>6 mo prior hormone or chemo tx; no prior RT;no neoadj.chemo for recurrent dz
<i>Vulva</i>	GOG 0279	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva	Locally-adv untreated squamous cell ca of the vulva.T2 or T3(N0-3, M0) not amenable to surgical resection by standard radical vulvectomy. PS 0-2. No prior pelvic RT or chemo.No vulvar melanomas or sarcomas; not eligible for higher priority GOG protocol

**HEAD & NECK**

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>Advanced (includes thyroid)</i>	RTOG 0920	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer	Squamous cell T1, N1-2 or T2-4a, N0-2, M0; no + margins;no prior chemo,anti-EGF or RT;PS 0-1;≥ 1 risk factor: perineural or lymph. invasion,1 node >3cm or ≥2+ nodes <6cm,close margin(s),T3 or T4a primary,T2 oral ca >5mm depth;T1-2, N0, M0 resected thyroid
<i>High Risk Squamous Cell</i>	RTOG 1216 (temp closed for credentialing)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck	Stage III or IV HNSCC; gross total surgical res; 1 high risk feature; no dist mets; Zubrod 0-1; no prior tx w/chemo; no prior rt; extracapsular nodal ext or close margins-within 3mm
<i>Oropharynx</i>	RTOG 1016 (QOL Component Closed)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer (HPV+)	Squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate or oropharyngeal walls) stage T1-2, N2a-3, or T3-4 any N; TUMOR MUST BE p16 POSITIVE. No mets; measurable dz; PS 0-1;No prior tx; Central path for review to confirm
<i>Recurrent/ Metastatic</i>	ECOG 1305	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer	Recurrent or metastatic SCCHN; no prior tx for recurrence/mets;no prior bevacizumab; prev. palliative RT OK if > 8 wks; surgery > 4 wks; no brain mets; no lung mets;no bleeding disorders; no chronic daily aspirin, PS 0-1
<i>Salivary Gland Tumors</i>	RTOG 1008	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors	Stage T3-4 or N1-3 or T1-2, N0 with a positive margin; high-grade mucoepidermoid carcinoma, high-grade adenocarcinoma, or salivary duct carcinoma; Surgical resection <8 wks; no mets; PS 0-1; No prior chemo or RT for salivary gland cancer
<i>Thyroid</i>	RTOG 0912 temp closed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel, and Pazopanib (NSC 737754)/Placebo for the Treatment of Anaplastic Thyroid Cancer	Anaplastic thyroid cancer;No brain mets;PS 0-2; No prior chemo for anaplastic thyroid cancer; No chemo or RT < 4 weeks of registration; No other investigational agents; No prior RT that would result in overlap of RT fields; No pts who require heparin
<b>LEUKEMIA</b>									
<i>AML (Older Adults)</i>	ECOG 2906 NOTE: Daunorubicin Shortage check with Pharmacy before enrolling	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Phase III Randomized Trial of Clofarabine as Induction & Post-Remission Tx vs Standard Daunorubicin & Cytarabine Induction & Intermediate Dose Cytarabine Post-Remission Tx, Followed by Decitabine Maint vs Observation in Newly-Diag AML in Adults ≥ 60 Years	≥ age 60;newly diag or secondary AML;no t (15;17)(q22;q21);no blastic trans of CML;no CNS; Must also enroll on ECOG 3903;PS 0-3;no prior tx with azacitidine, decitabine or low-dose cytarabine for AHD;prior hydroxyurea OK;bone marrow aspirate required
<i>AML (Ages 18-60)</i>	S1203 (not endorsed yet)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)	New dx AML; no prior chemo tx; 18-60 age; zubrod ≤3; mandatory bone marrow aspirate submission

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>CLL</i>	Connect CLL Registry	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Connect CLL: The Chronic Lymphocytic Leukemia Disease Registry	New diagnosis within 2 months of enrollment; >= age 18; able to read & speak English; agrees to complete all questionnaires; cannot participate in a treatment clinical study in which study treatment is blinded; life expectancy > 6 months
<i>Lab Study (for eligibility-mandatory with E2906)</i>	ECOG 3903	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders	Must be planing to enroll in an ECOG leukemia treatment clinical trial
<i>PNH</i>	PNH Registry	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Paroxysmal Nocturnal Hemoglobinuria (PNH) Subject Registry	Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) or a detected PNH clone. May or may not be receiving Soliris; also including patients previously treated with Soliris who have withdrawn from treatment.
<b>LUNG</b>									
<i>Mesothelioma</i>	CALGB 30901 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Randomized Phase II Study of Maintenance Pemetrexed Versus Observation For Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy	Completed 4 cycles of 1st line chemo w/ pemetrexed AND either cisplatin or carbo with CR, PR or stable dz; prior surgery and/or RT OK
<i>NSCLC</i>	Amgen Anemia 20070782	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety & Efficacy of Darbepoetin Alfa Administered at 500 ug Once-Every-3-Weeks in Anemic Subjects With Advanced Stage NSCLC Receiving Multi-cycle Chemotherapy	Stage IV NSCLC; must be receiving 2 cycles of 1st line chemo; PS 0-1 < 21 days randomization; Life Exp. > 6 mo; Hemoglobin ≤ 11.0 w/in 7 days rand; no prior adj or neoadj tx for NSCLC; no brain mets; no RBC transfusion or ESAs < 28 days;
<i>NSCLC</i>	RTOG 0813	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients	NSCLC, Stage T1-2, N0, M0;Tumor resectable; patient "medically inoperable"; Measurable dz<8 weeks; PS 0-2; No prior RT that would result in overlap of RT fields;No prior chemo;No other concurrent local therapy or systemic therapy
<i>NSCLC</i>	RTOG 0839	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer	Stage IIIA (T1-T3) (N1 or N2) meas dz; no palpable LN in the supraclavicular areas or higher unless benign by bx; no mets; PS 0-1;No prior chemo, biological tx or RT
<i>NSCLC</i>	TV1011-LC-303 TEVA LUNG (temp closed)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Multinational, Randomized, Open-label Phase III Study of Custirsen (TV-1011/OGX-011) in Combination with Docetaxel Versus Docetaxel as a Second-Line Treatment in Patients with Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer	Stage IV NSCLC; Life Exp. >12 wks;1 prior 1st line chemo; dz prog; meas dz; PS 0-1; >21 days prior tx;>2 wks RT; > 4 wks surgery; no CNS mets; no prev tx w/ docetaxel

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>NSCLC (need 2 cycles paclitaxel on hand to enroll)</i>	ECOG 3508	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer	Stage IV or recurrent non-squamous NSCLC; meas dz; treated brain mets OK; no prior tx for advanced dz; > 1 year prior tx; > 3 wks RT; > 4wks surgery; no concurrent cancer tx or anticoagulation tx; no HIV+ pts; no uncontrolled diabetes; PS 0-1;
<i>NSCLC Protocol Notice: Shortage of Paclitaxel</i>	ECOG 1505	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>= 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)	Completely resected, Stage IB (> 4 cm) – IIIA (T2-3N0, T1-3N1, T1-3N2 per AJCC 6th ed.); proper lymph node level resection; 6-12 weeks post surgery; PS 0-1; no prior chemo (Cisplat w/ Vinorelbine/Alimta/Gemzar-MD choice)
<i>SCLC</i>	CALGB 30610 (RTOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide	Limited stage SCLC; must have measurable dz; no contralateral hilar or supraclav lymph nodes; no prior RT; no prior mediastinal or thoracic RT; no complete surgical resection; PS 0-2
<i>SCLC (prophylactic Cranial RT for extensive disease)</i>	RTOG 0937	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)	Extensive stage SCLC ≤ 6 months; 1-3 extracranial mets; completed 4-6 courses of platinum-based chemo ≤ 8 wks AND one of the following: partial or complete response in ≥ 1 site of dz OR No progression in any site; PS 0-2; No brain or CNS mets;
<b>LYMPHOMA</b>									
<i>B CELL</i>	C05013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma	Pts previously untreated DLBCL subclassified as non-GCB subtype; least 1 measurable tumor mass that is > than 1.5 cm in the long axis and > than 1.0 cm in the short axis; No CNS lymphoma
<i>Follicular</i>	ECOG 2408	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma	Stage II, III, or IV AND grade 1, 2, or 3a; must have FLIPI-1 score of 3, 4, or 5 (1 point per criterion); Age ≥ 60, Stage III-IV, Hemoglobin level <12 g/dL, >4 nodal areas, Serum LDH level above normal; Meas dz; PS 0-2; No prior chemo, RT, or immunotherapy
<i>Mantle Cell</i>	ECOG 1411	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Intergroup Randomized Phase II Four Arm Study In Patients >= Age 60 with Previously Untreated Mantle Cell Lymphoma of Therapy with Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide	Age 60+; untreated mantle cell; meas dz; PS 0-2; no CNS; meas. dz; HIV+ OK (must meet criteria)
<b>MELANOMA</b>									
<i>Advanced, unresectable</i>	ECOG 3611	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-α in Advanced Melanoma	Unresectable stage III or IV; *primary or recurrent, cutaneous; 1 prior systemic tx OK; no prior tx w/ ipilimumab or other CTLA-4 inhibitor, or interferon-α for metastatic dz (adjuvant interferon-α OK); no autoimmune disorders; no brain mets; PS 0-1, meas dz

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>Mucosal, Acral, &amp; Solar</i>	ECOG 2607	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas	Metastatic or unresectable melanoma (acral, vagina and/or vulva, or other mucosal surface); meas. dz; must be KIT+; prior trt. OK, but NO targeted tx permitted; prior trt. > 4 weeks; CNS OK if treated and stable; PS 0-1 **Mandatory central review-tissue
<i>Resected, high-risk</i>	ECOG 1609	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon $\alpha$ -2b for Resected High-Risk Melanoma	Stage IIIB, IIIC, or IV (M1a or M1b); No ocular or mucosal melanoma; completely resected w/ neg margins <12 wks; Dz recurrence OK but see protocol; No prior adjuvant treatment after resection; >30 days RT; > 4wks IL-2 or other chemo; PS 0-1
<b>PREVENTION</b>									
<i>Colon</i>	P-5	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Statin Polyp Prevention Trial in Patients with Resected Colon Cancer	Stage 0, I, II or III adenocarcinoma of the colon w/ curative intent <1 year;complete resection;pre-op or post-op colonoscopy <180 days; >30 days since prior statins & prior investigational agents; no chronic use of NSAIDS (low dose aspirin OK);PS 0-1
<b>PROSTATE</b>									
<i>3D/IMRT</i>	RTOG 0534	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy	T3N0/Nx or T2N0/Nx with + or - margin; PSA DOUBLING TIME > 6 MONTHS PRIOR TO REG.; no hormones prior to reg; Zubrod 0-1, no mets; NO TIME LIMIT FROM PROSTECTOMY; No CNCMO, No RT; prostate Gleason $\leq$ 9, PSA $\geq$ 0.1 - <2.0
<i>3D/IMRT</i>	RTOG 0815	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer	Adenoca of the prostate diagnosed < 6 months; Gleason 7 or PSA > 10 but $\leq$ 20 ng/mL or stage T2b or T2c; Clinically negative lymph nodes; No evidence of bone mets; PS 0-1; no prior radical surgery, hormonal therapy, chemo or RT; No finasteride $\leq$ 30 days
<i>Favorable Risk</i>	RTOG 0938	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer	Adenoca of the prostate; T1-2a; Gleason 2-6; PSA < 10; PS 0-1; no prior or concurrent invasive dz; no mets; no LN involved; no prior pelvic surgery, chemo, RT or hormones; $\geq$ 30 days after finasteride use; $\geq$ 90 days after dutasteride use
<i>High Risk</i>	RTOG 1115	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer	Prostate adenoca;neg LN;PSA $\leq$ 150;no mets;PS 0-1;no prior radical prostatectomy,cryosurgery or bilateral orch;no prior chemo or hormones;no prior RT or brachy that would overlap fields;Gleason 7-9 with high risk for recurrence (see 3.1 for PSA & T-Stage)
<i>Intermediate or Favorable High Risk</i>	RTOG 0924	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial	Dx'd within past 180 days, GS 7-10 + T1c-T2b + PSA <50; GS 6 + T2c-T4 or >50% positive biopsies + PSA <50; GS 6 + T1c-T2b + PSA >20; no mets; no previous tx ; PS 0-1

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>Local Recurrence</i>	RTOG 0526	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy	Bx documented locally recurrent prostate adeno >30 months after EBRT and ≤ 180 days prior to reg; initial diagnosis T1-T2c, GS 2-6, PSA ≤20; OR T1-T2c, GS 7, PSA ≤10; N0; hormonal tx OK; no mets; PS 0-1; PSA<10
<i>Metastatic Hormone Sensitive</i>	S1216 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide In Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer	Prost ca w/ dist mets; no brain mets; neoadj/adj chemo &hormone therapy ok >2yrs; no prior chemo tx for mets; PSA≥2; zubrod 0-2; RT >14days; total androgen blockade for met dz <30days prior to reg
<i>Non-Metastatic Prostate Cancer</i>	RTOG 0622	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Trial of Samarium 153 Followed By Salvage Prostatic Fossa 3C-CRT or IMRT Irradiation In High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy	Prostate ca, stage T2-T4, N0-N1; no distant mets; postop PSA 2.0; or postop PSA rising above 0.2 with a surgical tumor Gleason score of 9 or 10; or rapidly rising PSA profile with a doubling time < 6 months; no prior chemo; no hormones < 3 months; PS 0-1
<b>SARCOMA</b>									
<i>Leiomyosarcoma</i>	GOG 0131-H Temp. Closed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus	Persistent or recurrent dz refractory to tx; meas. dz.;Not eligible for a higher priority GOG protocol; Must have had 1 prior regimen that included a taxane; no brain mets; PS 0-2; >1wk hormonal tx; >3 wks prior tx; >4 wks RT
<i>Leiomyosarcoma</i>	GOG 0277	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) versus Observation for Uterus-limited, High Grade Uterine Leiomyosarcoma	High risk uterine LMS, FIGO stage I; had complete hysterectomy; no mets; PS 0-1; no prior chemo with docetaxel, gemcitabine or doxorubicin ever; no prior whole pelvic RT; no recurrent LMS; no HIV
<i>Liposarcoma or Leiomyosarcoma</i>	ET743-SAR-3007	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide	Locally advanced or spreading liposarcoma or leiomyosarcoma that is unable to be removed by surgery; prior tx with an anthracycline & ifosfamide; Meas dz; PS 0-1; no prior tx with trabectedin or dacarbazine; > 3 weeks from prior tx; no CNS mets
<b>SPINE</b>									
<i>Metastatic</i>	RTOG 0631	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	(ACH ONLY) Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis	Localized spine metastasis from C1 to L5, a solitary spine metastasis; two sep. spine levels; or up to 3 separate site, Zubrod 0-2
<b>SUPPORTIVE CARE</b>									
<i>HER2-Positive</i>	SCUSF 0806 (not endorsed yet)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®)	HER2-positive breast ca; males ok; Scheduled to receive adjuvant or neoadjuvant trastuzumab therapy; Hormone receptor and menopausal status not specified; No prior trastuzumab or anthracyclines; No known cardiac history; no met dz; no ARB's

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>NSCLC</i>	Amgen Anemia 20070782	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety & Efficacy of Darbepoetin Alfa Administered at 500 ug Once-Every-3-Weeks in Anemic Subjects With Advanced Stage NSCLC Receiving Multi-cycle Chemotherapy	Stage IV NSCLC; must be receiving 2 cycles of 1st line chemo; PS 0-1 < 21 days randomization; Life Exp. > 6 mo; Hemoglobin ≤ 11.0 w/in 7 days rand; no prior adj or neoadj tx for NSCLC; no brain mets; no RBC transfusion or ESAs < 28 days;
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0267 QOL STUDY	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian tube, and Peritoneal Cancer	Recurrent or persistent ovarian, peritoneal or fallopian tube platinum-resistant cancer(< 6 months from date of last platinum tx to recurrence); life expectancy > 6 months; any PS but must be able to verbally consent and participate in the first assessment
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0273 ≥ age 70	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	GOG 0273 Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer	≥ age 70;Adenoca of ovary, peritoneum or fallopian tube;FIGO I, II, III & IV;no prior tx except for surgery;register ≤ 8 weeks confirmation of dx or 12 wks of primary/staging surgery;PS 0-3;phys choice primary surgery vs chemo + 2 chemo regimen choices